Feasibility and safety of minimized cardiopulmonary bypass in major aortic surgery

Aziz U Momin, Mansour T A Sharabiani, Emadin Kidher, Ali Najefi, John W Mulholland, Barnaby C Reeves, Gianni D Angelini, Jon R Anderson

Research output: Contribution to journalArticle (Academic Journal)

10 Citations (Scopus)


OBJECTIVESConventional cardiopulmonary bypass causes haemodilution and is a trigger of systemic inflammatory reactions, coagulopathy and organ failure. Miniaturized cardiopulmonary bypass has been proposed as a way to reduce these deleterious effects of conventional cardiopulmonary bypass and to promote a more physiological state. The use of miniaturized cardiopulmonary bypass has been reported in low-risk patients undergoing valve and coronary artery bypass graft (CABG) surgery. However, little is known about its application in major aortic surgery.METHODSFrom February 2007 to September 2010, 49 patients underwent major aortic surgery using the Hammersmith miniaturized cardiopulmonary bypass (ECCO, Sorin). Data were extracted from medical records to characterize preoperative comorbidities (EuroSCORE), perioperative complications and the use of blood products. The same data were collected and described for 328 consecutive patients having similar surgery with conventional cardiopulmonary bypass at the Bristol Heart Institute, our twinned centre, during the same period.RESULTSThe miniaturized cardiopulmonary bypass group had a median EuroSCORE of 8 [inter-quartile range (IQR): 5-11], 13% had preoperative renal dysfunction and 20% of operations were classified as emergency or salvage. Thirty-day mortalities were 6.4; and 69, 67 and 74% had ≥1 unit of red cells, fresh frozen plasma (FFP) and platelets transfused, respectively. Eight percent of patients experienced a renal complication, and 8% a neurological complication. The conventional cardiopulmonary bypass group was similar, with a EuroSCORE of 8 (IQR: 6-10); 30-day mortalities were 9.4; and 68, 62 and 74% had ≥1 unit of red cells, FFP and platelets transfused, respectively. The proportions experiencing renal and neurological complications were 14 and 5%.CONCLUSIONSOur experience suggests that miniaturized cardiopulmonary bypass is safe and feasible for use in major aortic cardiac surgery. A randomized trial is needed to evaluate miniaturized cardiopulmonary bypass formally.
Original languageEnglish
JournalInteractive Cardiovascular and Thoracic Surgery
Publication statusPublished - 28 Jun 2013

Structured keywords

  • BTC (Bristol Trials Centre)
  • Centre for Surgical Research

Fingerprint Dive into the research topics of 'Feasibility and safety of minimized cardiopulmonary bypass in major aortic surgery'. Together they form a unique fingerprint.

  • Cite this